A Quebec woman is the first person in Canada to develop the rare blood clotting complication known as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) that has been seen in some individuals who have received the AstraZeneca COVID-19 vaccine. The vaccine is currently recommended for use in people aged 55 and older as a small number of clotting events in people under 55 were reported in Europe. This report is the first in Canada, out of 500,000 doses of the AstraZeneca vaccine that have been administered. The individual is recovering well.